

Mal-(CH2)5-Val-Cit-PAB-Eribulin Biochemical

Mal-(CH2)5-Val-Cit-PAB-Eribulin

CATALOG #
AAA228141


PRODUCT SYNONYMS

Mal-(CH2)5-Val-Cit-PAB-Eribulin; Mal-(CH2)5-Val-Cit-PAB-Eribulin biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2130869-21-3
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules[2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
PROTAC BRD4 Degrader-15, CAS 2417370-67-1



Structure
PROTAC BRD4 Degrader-15, CAS 2417370-67-1

ADDITIONAL INFORMATION

Related Product Information for Mal-(CH2)5-Val-Cit-PAB-Eribulin biochemical	Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.
References	1. Dragovich PS, et, al. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy. J Med Chem. 2021 Mar 11;64(5):2576-2607.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.